Larry Greenfield

Title: **Larry Greenfield: Innovator in Immunotoxin Development**

Introduction

Larry Greenfield is an accomplished inventor based in Emeryville, California, known for his significant contributions in the field of immunotoxin therapy. With a total of two patents to his name, Greenfield has focused his work on the development of advanced treatments for human tumors and leukemias, making strides in the fight against cancer.

Latest Patents

Larry Greenfield's latest patents include groundbreaking work on “Mutant diphtheria toxin conjugates,” which detail a potent and specific immunotoxin prepared by coupling an inactivated diphtheria toxin to a binding moiety, such as a monoclonal antibody or transferrin. This innovative immunotoxin is specifically designed for human tumors and leukemias, displaying toxicity profiles that are indistinguishable from that of the native toxin while avoiding harm to other cells. The applications of this immunotoxin extend to treating graft versus host disease, as well as selectively targeting and killing tumor cells, including medulloblastoma and glioblastoma cells. Additionally, he holds a patent for the “Method of preparing diphtheria immunotoxins,” which elaborates on the same principles of coupling inactivated diphtheria toxins to binding moieties to enhance therapeutic efficacy.

Career Highlights

Throughout his career, Larry Greenfield has made substantial contributions to the field of biomedical research. He has worked with notable organizations such as Cetus Corporation and the United States of America, where he has been involved in pioneering research and development initiatives.

Collaborations

Greenfield has collaborated with esteemed colleagues, including Virginia G. Johnson and Richard J. Youle. These partnerships have enabled the exchange of ideas and advancements in the research and application of immunotoxins.

Conclusion

Larry Greenfield’s innovative work in the area of diphtheria immunotoxins represents a significant advancement in cancer treatment and immunotherapy. His patents encapsulate a commitment to developing targeted therapies that promise to improve outcomes for patients suffering from challenging diseases like cancers and graft versus host disease. Through his collaborations and career endeavors, Greenfield continues to be a formidable presence in the field of biomedical innovation.